The agreement with Singular has provided strategic business consulting, product development, and brand marketing services to Lifeist and its operating divisions during a critical period of time for ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced a presentation at the American Academy of Ophthalmology (AAO) 2024 Expo, ...

Despite a significant net loss, Eyenovia Inc (EYEN) progresses with innovative technologies and promising collaborations in ...

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today announced that the Company has commenced manufacturing of registration batches of its ...

NEW YORK - Eyenovia, Inc. (NASDAQ: NASDAQ:EYEN), an ophthalmic technology firm, has announced the U.S. commercial availability of its FDA-approved clobetasol propionate ophthalmic suspension 0.05% ...

Abidin Gülmüş, Chairman of GEN, stated: "We are thrilled to announce the positive results of our Phase 2 clinical trial. We believe GN-037 offers new hope for the global psoriasis community." Founded ...

Ehsan Sadri, MD, FACS, of Visionary Eye Institute in Newport Beach, California, sat down with Professor Emeritus Colin R. Green, PhD, DSc, University of Auckland, in Auckland, New Zealand, to learn ...

Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension 0.05% for pain and inflammation following ...